VALLEY FORGE, Pa.--(BUSINESS WIRE)--Feb. 9, 2017--
The Board of Directors of AmerisourceBergen Corporation (NYSE: ABC)
today declared a quarterly dividend of $0.365 per common share, payable
March 6, 2017, to stockholders of record at the close of business on
February 21, 2017.
About AmerisourceBergen
AmerisourceBergen is one of the largest global pharmaceutical sourcing
and distribution services companies, helping both healthcare providers
and pharmaceutical and biotech manufacturers improve patient access to
products and enhance patient care. With services ranging from drug
distribution and niche premium logistics to reimbursement and
pharmaceutical consulting services, AmerisourceBergen delivers
innovative programs and solutions across the pharmaceutical supply
channel in human and animal health. With over $145 billion in annual
revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and
employs approximately 19,000 people. AmerisourceBergen is ranked #12 on
the Fortune 500 list. For more information, go to www.amerisourcebergen.com.
AmerisourceBergen's Cautionary Note Regarding Forward-Looking
Statements
Certain of the statements contained in this press release are
"forward-looking statements" within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of
1934. Words such as "expect," "likely," "outlook," "forecast," "would,"
"could," "should," "can," "will," "project," "intend," "plan,"
"continue," "sustain," "synergy," "on track," "believe," "seek,"
"estimate," "anticipate," "may," "possible," "assume," variations of
such words, and similar expressions are intended to identify such
forward-looking statements. These statements are based on management's
current expectations and are subject to uncertainty and change in
circumstances. These statements are not guarantees of future performance
and are based on assumptions that could prove incorrect or could cause
actual results to vary materially from those indicated. Among the
factors that could cause actual results to differ materially from those
projected, anticipated, or implied are the following: unfavorable trends
in brand and generic pharmaceutical pricing, including in rate or
frequency of price inflation or deflation; competition and industry
consolidation of both customers and suppliers resulting in increasing
pressure to reduce prices for our products and services; changes in
pharmaceutical market growth rates; substantial defaults in payment,
material reduction in purchases by or the loss, bankruptcy or insolvency
of a major customer; changes to the customer or supplier mix; the
retention of key customer or supplier relationships under less favorable
economics or the adverse resolution of any contract or other dispute
with customers or suppliers; changes to customer or supplier payment
terms; the disruption of AmerisourceBergen's cash flow and ability to
return value to its stockholders in accordance with its past practices;
risks associated with the strategic, long-term relationship
between Walgreens Boots Alliance, Inc. and AmerisourceBergen, including
with respect to the pharmaceutical distribution agreement and/or the
global sourcing arrangement; changes in the United States healthcare and
regulatory environment, including changes that could impact prescription
drug reimbursement under Medicare and Medicaid; increasing governmental
regulations regarding the pharmaceutical supply channel and
pharmaceutical compounding; federal and state government enforcement
initiatives to detect and prevent suspicious orders of controlled
substances and the diversion of controlled substances; federal and state
prosecution of alleged violations of related laws and regulations, and
any related litigation, including shareholder derivative lawsuits or
other disputes relating to our distribution of controlled substances;
increased federal scrutiny and qui tam litigation for alleged violations
of fraud and abuse laws and regulations and/or any other laws and
regulations governing the marketing, sale, purchase and/or dispensing of
pharmaceutical products or services and any related litigation; material
adverse resolution of pending legal proceedings; declining reimbursement
rates for pharmaceuticals; the acquisition of businesses that do not
perform as expected, or that are difficult to integrate or control,
including the integration of PharMEDium, or the inability to capture all
of the anticipated synergies related thereto; regulatory action in
connection with the production, labeling or packaging of products
compounded by our compounded sterile preparations (CSP) business;
declining economic conditions in the United States and abroad; financial
market volatility and disruption; the loss, bankruptcy or insolvency of
a major supplier; interest rate and foreign currency exchange rate
fluctuations; managing foreign expansion, including non-compliance with
the U.S. Foreign Corrupt Practices Act, anti-bribery laws and economic
sanctions and import laws and regulations; malfunction, failure or
breach of sophisticated information systems to operate as designed;
risks generally associated with data privacy regulation and the
international transfer of personal data; changes in tax laws or
legislative initiatives that could adversely
affect AmerisourceBergen's tax positions and/or AmerisourceBergen’s tax
liabilities or adverse resolution of challenges
to AmerisourceBergen's tax positions; natural disasters or other
unexpected events that affect AmerisourceBergen's operations; the
impairment of goodwill or other intangible assets, resulting in a charge
to earnings; and other economic, business, competitive, legal, tax,
regulatory and/or operational factors
affecting AmerisourceBergen's business generally. Certain additional
factors that management believes could cause actual outcomes and results
to differ materially from those described in forward-looking statements
are set forth (i) in Item 1A (Risk Factors) in the Company’s Annual
Report on Form 10-K for the fiscal year ended September 30, 2016 and
elsewhere in that report and (ii) in other reports filed by the Company
pursuant to the Securities Exchange Act.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170209005764/en/
Source: AmerisourceBergen Corporation
AmerisourceBergen Corporation
Keri P. Mattox
Vice
President, Corporate & Investor Relations
610-576-7801
kmattox@amerisourcebergen.com
or
Bennett
S. Murphy
Manager, Corporate & Investor Relations
610-727-3693
bmurphy@amerisourcebergen.com